Literature DB >> 9816237

Tumor necrosis factor alpha enhances secretion of transforming growth factor beta2 in MCF-7 breast cancer cells.

D N Danforth1, M K Sgagias.   

Abstract

We studied the effect of tumor necrosis factor alpha (TNF-alpha) on transforming growth factor beta (TGF-beta) secretion by human breast cell lines to further characterize the antitumor effects of TNF-alpha. We found that TNF-alpha increased the secretion of TGF-beta in two established breast cancer cell lines (MCF-7 and ZR-75-1) but not in two immortalized human mammary epithelial cell lines (184B5 and MCF-10A). In MCF-7 cells, TNF-alpha increased the secretion of total TGF-beta 6.1-fold within 72 h in a dose-dependent manner. The secretion of both latent and active forms of TGF-beta was increased, and their ratio altered from 25:1 to 12:1 in the medium. TNF-alpha converted the secretory pattern of TGF-beta by MCF-7 cells from the heterodimeric form TGF-beta1.2 to the homodimeric form TGF-beta2. Immunoblot analysis under nonreducing conditions identified four molecular mass species of TGF-beta secreted in the culture media of untreated MCF-7 cells (238, 210, 40-55, and 25 kDa). Under reducing conditions, three molecular mass species of TGF-beta were identified: 88, 44, and 12 kDa. Gel filtration analysis demonstrated that the secreted TGF-beta within the range of 12-88 kDa was biologically active. TNF-alpha treatment did not alter the size of molecular mass species secreted by MCF-7 cells and did not change steady-state levels of mRNA for TGF-beta1 or TGF-beta2. These findings indicate that TNF-alpha may regulate quantitatively and qualitatively TGF-beta secretion by human breast cancer cells in vitro. The diverse biological activities of TGF-beta may also allow TNF-alpha to regulate the growth and metabolism of human mammary epithelial cells and/or stromal cells in a paracrine manner.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816237

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  Cancer cells remodel themselves and vasculature to overcome the endothelial barrier.

Authors:  Anitha K Shenoy; Jianrong Lu
Journal:  Cancer Lett       Date:  2014-10-31       Impact factor: 8.679

Review 3.  Therapeutic implications of the TGF-beta system.

Authors:  B A Arrick
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

Review 4.  IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Authors:  Claire M Perks; Jeff M P Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

5.  Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Authors:  Kang-Ling Liao; Xue-Feng Bai; Avner Friedman
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 6.  Homeostatic Signaling by Cell-Cell Junctions and Its Dysregulation during Cancer Progression.

Authors:  Yang Yu; Randolph C Elble
Journal:  J Clin Med       Date:  2016-02-18       Impact factor: 4.241

7.  Mechanistic evidence that benzo[a]pyrene promotes an inflammatory microenvironment that drives the metastatic potential of human mammary cells.

Authors:  Durr-E-Shahwar Malik; Rhiannon M David; Nigel J Gooderham
Journal:  Arch Toxicol       Date:  2018-08-24       Impact factor: 5.153

8.  Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells.

Authors:  Zhihong Chen; Yinlin Ge; Natalie Landman; Jing X Kang
Journal:  BMC Cancer       Date:  2002-07-30       Impact factor: 4.430

9.  Down-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes.

Authors:  Zhihong Chen; Yinlin Ge; Jing X Kang
Journal:  BMC Cell Biol       Date:  2004-04-28       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.